Association between oxidative stress parameters and inflammation markers according to the gravity of the acute coronary syndrome

##plugins.themes.academic_pro.article.sidebar##

Published Jul 12, 2011
Download
pdf
Vol. 89 No. 7 (2011): Issue Jul 2011

##plugins.themes.academic_pro.article.main##

Amel Nakbi
Nadia Koubaa
Khaldoun Ben Hamda
Sonia HAMMAMI
Nabil Attia
Radhia Boumiza
Abdelhedi Miled
Mohamed Ben Farhat
Service de Cardiologie
Mohamed Hammami

Abstract

Background: Cardiovascular disease is the consequence of appearance and development of atherosclerosis lesions of associated with a inflammatory complication.
Aim: To elucidate a possible association between several inflammation and oxidative stress markers according to the severity of coronary artery disease.
Methods: This study was carried on 93 coronary subjects with: unstable angina (UA; n=42); stable angina (SA; n=15) and acute myocardial infarction (AMI; n=36) and 140 control subjects to whom lipidic, oxidative and inflammatory parameters were determined.
Results: In addition to a moderate hyperhomocysteinemia observed in the coronary artery disease, a significant higher levels of the oxidized LDL (ox-LDL) were found among these patients (p< 0.001). A positive correlation was found between the markers of the inflammation and the gravity of the acute coronary syndrome.
One note a significant increase of the rate of ox-LDL and high sensitive CRP to AMI by reports in UA and SA (p=0.00, and p=0.001 respectively) which is linked to an elevation of the plasmatic concentration of the total homocysteine.
Conclusion: This study suggests an association between the markers of the inflammation and oxidative parameters in the acute coronary syndrome.

Keywords:

ox-LDL, homocysteine, hsCRP, MDA, Acute Coronary Syndrome, gravity

##plugins.themes.academic_pro.article.details##

References

  1. Braunwald E. Cardiovascular medicine at the turn of the millenium: triumphs, concerns, and opportunities. N Eng J Med 1997; 337 :1360-9.
  2. Quilici J, Gallo R. Physiopathologie des syndromes coronariens aigus. Ann Cardiol Angéiol 1999; 48 :611-23.
  3. Steinberg D. lipoprotein and the pathogenesis of atherosclerosis. Circulation 1987; 76 :508-14.
  4. Young I. S, McEneny J. Lipoprotein oxidation and atherosclerosis. Biochemical Society Transactions 2001; 29 :358- 62.
  5. P. Duriez. Mécanismes de formation de la plaque d'athérome. Rev Med Interne 2004; 25 :S3-S6.
  6. Brattström L, Wilcken D.E.L. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000; 72:315-23.
  7. Li H, Cybulsky MI, Gimbrone MA Jr, Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb 1993; 13 :197-204.
  8. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-90.
  9. Engler R. Protéine de la réaction inflammatoire. Ann Biol Clin 1988; 46 :336-42.
  10. Smaoui M, Hammami S, Chaaba R et al. Lipids and lipoprotein (a) concentration in Tunisian Type 2 diabetic patients relationship to glycaemic control and coronary heart disease. J Diabetes Complications 2004; 18 : 258-63.
  11. Koubaa N, Nakbi A, Smaoui M, et al. Hyperhomocysteinemia and elevated ox-LDL in Tunisian type 2 diabetic patients: role of genetic and dietary factors. Clin Biochem. 2007; 40: 1007-14.
  12. Ehara S, Ueda M, Naruko T, et al. Elevated levels of low-density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001; 103 :1955-60
  13. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: Clinical importance. Curr Probl Cardiol 2004; 29: 439- 93.
  14. Ben Romthane H, Bougatef S, Skiri H, et al. The first tunisian cardiovascular diseases register: process and results. Rev Epidemiol Sante publique 2004; 52: 558-64.
  15. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. 5-year incidence of atherosclerotic vasculmar disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non insulin-dependant diabetic and non diabetic subjects. Circulation 1990; 82: 27-36.
  16. Ginon I, André-Fouet X. Hyperlipidémies et risque cardiovasculaire. Encycl Med Chir. Endocrinologie -Nutrition 2000; 10-368-H10 :1-9.
  17. Stamler J, Wentworth DN, Neaton JD, for the MRFIT group. Is relationship between serum cholesterol and risk of premature death from coroary heart disease continous and graded? Findings in 356 222 primary screenees of the MRFIT. JAMA 1986; 256: 2823-28.
  18. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidenceof coronary heart disease and lipoprotein cholesterol levels. The Framingham study. Jama 1986; 256 :2835-38.
  19. Castelli WP. The new pathophysiology of coronary artery disease .Am j Cardiol 1998; 82 :60T-65T.
  20. Hoogeveen EK, Kostense PJ, Beks PJ, et al. Hyperhomocysteinaemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 1998; 18 :133-8
  21. Baydas G, Reiter RJ, Akbulut M, Tuzcu M, Tamer S. Melatonin inhbits neural apoptosis induced by homocysteine in hippocampus of rats via inhibition of cytochrome c translocation and caspase-3 activation and by regulating pro- ad anti-apoptotic protein levels. Neuroscience 2005; 135: 879-86.
  22. Tyagi N, Moshal KS, Ovechkin AV, et al. Mitochondrial mechanism of oxidative stresss and systemic hypertension in hyperhomocystéinemie. J Cell Biochem 2005; 96:665-71.
  23. Stamler J.S., Osborne J.A., Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91:308-18.
  24. Shoichi Ehara, Makiko Ueda, Takahiko Naruko, et al. Elevated Levels of Oxidized Low Density Lipoprotein Show a Positive Relationship With the Severity of Acute Coronary Syndromes. Circulation 2001; 103:1955-60.
  25. Koubaa N., Nakbi A., Smaoui M. Impact des habitudes de type2 originaires du Sud et du Sahel. RMEDR 2007; 12 :161-259.
  26. Kasdallah-Grissa A., Nakbi A, Koubaa N., et al. Supplementation of virgin olive oil reduces oxidative damage in the livers of rats treated with ethanol. Nutr Res 2008; 28 : 472- 79.
  27. Lecarpentier Y, Coirault C, Chenk D. Régulation cellulaire et moléculaire de la contraction cardiaque. Médecine thérapeutique 1996; 2 :301-10.
  28. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105 :1135-43.
  29. Ridker PM. High sensitivity C reactiv protein: potentiel adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103:1813-18.
  30. Sirol M., Bouzamondo A., Sanchez P, Lechat P. Les satines préviennent-elles le risque d'accident vasculaire cérébral? Ann Med Interne 2001; 152 :188-93.
  31. Ridker PM, Rifai N, Clearfield M, et al., Measurement of Creactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J M 2001; 344: 2016-2018.
  32. Kwak B., Mulhaupt F., Mytt S.and Mach F. Statins as a newly recognized type of immunomodulator. Nat M 2000; 6:1399-1402.
  33. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of Creactive protein of discharge in patients with unstable angina predict recurrent instability.Circulation 1999; 99: 855-60.
  34. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331 :417-24.
  35. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481-5.